tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

PROK Stock Latest News

ProKidney Sells Greensboro Property for $19.1 Million
Company AnnouncementsProKidney Sells Greensboro Property for $19.1 Million
4d ago
8K
PROK
ProKidney: Hold Rating Amid Encouraging Developments and Cautious Outlook
PremiumRatings
ProKidney: Hold Rating Amid Encouraging Developments and Cautious Outlook
2M ago
PROK
ProKidney Corp. Reports Q2 2025 Financial Results
PremiumCompany Announcements
ProKidney Corp. Reports Q2 2025 Financial Results
2M ago
PROK
ProKidney reports Q2 EPS (13c), consensus (14c)
PremiumThe Fly
ProKidney reports Q2 EPS (13c), consensus (14c)
2M ago
PROK
Prokidney Corp options imply 15.7% move in share price post-earnings
PremiumThe Fly
Prokidney Corp options imply 15.7% move in share price post-earnings
2M ago
PROK
Prokidney Corp options imply 13.0% move in share price post-earnings
PremiumThe FlyProkidney Corp options imply 13.0% move in share price post-earnings
3M ago
PROK
Prokidney’s REACT Study: A Promising Step for Kidney Disease Treatment
Premium
Company Announcements
Prokidney’s REACT Study: A Promising Step for Kidney Disease Treatment
3M ago
PROK
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
3M ago
AISP
AVXL
ProKidney’s Hold Rating: Balancing FDA Alignment and Extended Approval Timeline
PremiumRatings
ProKidney’s Hold Rating: Balancing FDA Alignment and Extended Approval Timeline
3M ago
PROK
ProKidney’s Clinical Trials and Regulatory Developments Lead to Hold Rating Amid Uncertainty
PremiumRatings
ProKidney’s Clinical Trials and Regulatory Developments Lead to Hold Rating Amid Uncertainty
3M ago
PROK
ProKidney’s Strategic FDA Alignment and Promising Clinical Data Drive Buy Rating
PremiumRatings
ProKidney’s Strategic FDA Alignment and Promising Clinical Data Drive Buy Rating
3M ago
PROK
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
3M ago
AZ
VOR
ProKidney Secures FDA Alignment for Rilparencel Approval
PremiumCompany AnnouncementsProKidney Secures FDA Alignment for Rilparencel Approval
3M ago
8K
PROK
ProKidney announces alignment with FDA on rilparencel accelerated approval path
Premium
The Fly
ProKidney announces alignment with FDA on rilparencel accelerated approval path
3M ago
PROK
ProKidney price target raised to $8 from $4 at UBS
Premium
The Fly
ProKidney price target raised to $8 from $4 at UBS
3M ago
PROK
ProKidney Enters New $200M Sale Agreement with Jefferies
PremiumCompany Announcements
ProKidney Enters New $200M Sale Agreement with Jefferies
3M ago
8K
PROK
ProKidney price target raised to $7 from $6 at Guggenheim
PremiumThe Fly
ProKidney price target raised to $7 from $6 at Guggenheim
3M ago
PROK
Nvidia hits $4T market cap, Merck acquires Verona Pharma: Morning Buzz
PremiumThe Fly
Nvidia hits $4T market cap, Merck acquires Verona Pharma: Morning Buzz
3M ago
BA
EXK
Why Is ProKidney Stock (PROK) Up 60% Today?
PremiumMarket News
Why Is ProKidney Stock (PROK) Up 60% Today?
3M ago
PROK
ProKidney’s Hold Rating: Balancing Promising Phase 2 Results with Future Uncertainties
PremiumRatingsProKidney’s Hold Rating: Balancing Promising Phase 2 Results with Future Uncertainties
3M ago
PROK
Hold Rating for ProKidney Amid Promising Phase 2 Results and Regulatory Uncertainty
Premium
Ratings
Hold Rating for ProKidney Amid Promising Phase 2 Results and Regulatory Uncertainty
3M ago
PROK
ProKidney price target raised to $9 from $6 at Citi
Premium
The Fly
ProKidney price target raised to $9 from $6 at Citi
4M ago
PROK

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >